Next Generation CAR & T Cell Therapies is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Harjeet Singh
Instructor, Department of Pediatrics at UT MD Anderson Cancer Center, USA


Dr. Singh is an Instructor at The University of Texas MD Anderson Cancer Center, specializing in development and application of novel immunotherapeutic modalities. Dr. Singh received his PhD in Biochemistry, and trained in the labs of Drs. Ravi Bhatia and Laurence Cooper investigating the biology of hematologic malignancies and creating genetically modified T-cells to treat them. He has more than 10 years of experience in generating CARs and evaluating efficacy at a single cell level using biomarker analysis. His work has helped launch more than 10 investigator-initiated clinical trials evaluating both natural killer (NK) and T-cells.

Harjeet Singh's Network

Agenda Sessions

  • Genetic modification of T cells to express CD19-specific CAR in two days

    , 2:45pm